Laurel Wealth Advisors LLC Sells 140 Shares of DexCom, Inc. (NASDAQ:DXCM)

Laurel Wealth Advisors LLC reduced its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 16.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 728 shares of the medical device company’s stock after selling 140 shares during the period. Laurel Wealth Advisors LLC’s holdings in DexCom were worth $90,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of DXCM. Sands Capital Management LLC boosted its position in DexCom by 10.2% during the fourth quarter. Sands Capital Management LLC now owns 15,058,806 shares of the medical device company’s stock valued at $1,868,647,000 after purchasing an additional 1,398,136 shares during the last quarter. Artisan Partners Limited Partnership boosted its holdings in shares of DexCom by 164.8% in the 4th quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock valued at $732,169,000 after buying an additional 3,672,471 shares during the last quarter. Blair William & Co. IL grew its stake in shares of DexCom by 1.7% in the third quarter. Blair William & Co. IL now owns 4,507,153 shares of the medical device company’s stock valued at $420,517,000 after buying an additional 73,654 shares in the last quarter. Norges Bank acquired a new position in DexCom during the fourth quarter worth $540,178,000. Finally, Northern Trust Corp raised its position in DexCom by 2.4% during the third quarter. Northern Trust Corp now owns 3,896,515 shares of the medical device company’s stock worth $363,545,000 after acquiring an additional 91,249 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Citigroup lifted their price objective on shares of DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Canaccord Genuity Group raised their price objective on shares of DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a research report on Friday. Royal Bank of Canada assumed coverage on DexCom in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 target price on the stock. StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a report on Tuesday, April 23rd. Finally, UBS Group lifted their target price on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. Three analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $141.67.

DexCom Price Performance

Shares of DexCom stock traded up $1.47 during trading on Monday, reaching $125.81. 3,845,948 shares of the company’s stock were exchanged, compared to its average volume of 3,056,784. The firm’s 50-day moving average price is $131.30 and its 200 day moving average price is $119.17. The company has a market cap of $50.03 billion, a P/E ratio of 81.17, a PEG ratio of 2.11 and a beta of 1.20. The company has a debt-to-equity ratio of 1.08, a quick ratio of 2.53 and a current ratio of 2.90. DexCom, Inc. has a 1-year low of $74.75 and a 1-year high of $142.00.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. The firm had revenue of $921.00 million during the quarter, compared to analysts’ expectations of $911.20 million. DexCom had a net margin of 16.82% and a return on equity of 31.01%. As a group, research analysts anticipate that DexCom, Inc. will post 1.78 earnings per share for the current year.

Insider Buying and Selling at DexCom

In other news, CFO Jereme M. Sylvain sold 3,363 shares of the stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total value of $392,562.99. Following the completion of the transaction, the chief financial officer now directly owns 71,142 shares in the company, valued at approximately $8,304,405.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other DexCom news, EVP Sadie Stern sold 20,321 shares of the company’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $133.61, for a total value of $2,715,088.81. Following the completion of the transaction, the executive vice president now directly owns 80,441 shares in the company, valued at approximately $10,747,722.01. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Jereme M. Sylvain sold 3,363 shares of DexCom stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total transaction of $392,562.99. Following the transaction, the chief financial officer now owns 71,142 shares in the company, valued at approximately $8,304,405.66. The disclosure for this sale can be found here. Insiders have sold 189,375 shares of company stock worth $25,530,859 over the last quarter. Corporate insiders own 0.41% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.